FDA to approve photodynamics for lung cancer:
This article was originally published in Clinica
Laserscope has obtained an approvable letter from the FDA for its photodynamic therapy in late-stage lung cancer. The FDA has already approved the technique for the much less common obstructive oesophageal cancers. In PDT, patients are endoscopically injected with porfimer sodium, a light-activated drug that is selectively absorbed by malignant cells. Another laser supplier, Coherent, has also applied for the same licence.
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.